Natural Product (NP) Details
General Information of the NP (ID: NP3051) | |||||
---|---|---|---|---|---|
Name |
Pregabalin
|
||||
Synonyms |
Pregabalin; 148553-50-8; Lyrica; (S)-3-(Aminomethyl)-5-methylhexanoic acid; 3-isobutyl GABA; (3S)-3-(aminomethyl)-5-methylhexanoic acid; CI-1008; (S)-Pregabalin; Hexanoic acid, 3-(aminomethyl)-5-methyl-, (3S)-; CI 1008; PD 144723; UNII-55JG375S6M; PD-144723; (S)-3-Isobutyl GABA; CHEMBL1059; CHEBI:64356; (3S)-3-(aminomethyl)-5-methyl-hexanoic acid; 55JG375S6M; MFCD00917044; Hexanoic acid, 3-(aminomethyl)-5-ethyl-, (3S)-; (R-)-3-isobutyl GABA; Hexanoic acid, 3-(aminomethyl)-5-methyl-, (S)-; Nervalin; Pregablin; HSDB 7530; Pregabalin [USAN:INN:BAN:JAN]; NCGC00095186-01; Lyrica (TN); (S)-3-(Aminomethyl)-5-methylhexanoicacid; SCHEMBL8227; DSSTox_CID_25950; DSSTox_RID_81246; DSSTox_GSID_45950; Pregabalin (JAN/USAN/INN); (S)-(+)-4-amino-3-(2-methylpropyl)butanoic acid; GTPL5484; ZINC5152; DEA No. 2782; Pregabalin, >=97% (NMR); DTXSID1045950; HMS3715J16; Pregabalin 1.0 mg/ml in Methanol; YNP-1807; Tox21_111475; BDBM50164279; CP0100; AKOS001476611; AKOS005145504; Lyrica;CI-1008;PD-144723; AC-1158; ACN-038395; CCG-221247; CM14412; CS-1247; DB00230; KS-5378; NSC 759256; (S)-3-aminomethyl-5-methylhexanoic acid; NCGC00346738-01; 121GE001; HY-17414; (S)-3-Aminomethyl-5-methyl-hexanoic acid; AB0074009; AM20080369; CAS-148553-50-8; EN300-92104; (3S)-3-(aminomethyl)-5-methyl hexanoic acid; (S)-(+)-3-Aminomethyl-5-Methylhexanoic Acid; D02716; W-5218; AB01563007_01; 553P508; A808784; Q412174; SR-01000942257; SR-01000942257-2; Pregabalin, EuropePharmacopoeia (EP) Reference Standard; Z2757554242; 1414928-41-8
Click to Show/Hide
|
||||
Species Origin | Homo sapiens ... | Click to Show/Hide | |||
Homo sapiens | |||||
Disease | Chronic obstructive pulmonary disease [ICD-11: CA22] | Approved | [1] | ||
Structure |
Click to Download Mol2D MOL |
||||
Click to Show/Hide the Molecular Information and External Link(s) of This Natural Product | |||||
Formula |
C8H17NO2
|
||||
PubChem CID | |||||
Canonical SMILES |
CC(C)CC(CC(=O)O)CN
|
||||
InChI |
1S/C8H17NO2/c1-6(2)3-7(5-9)4-8(10)11/h6-7H,3-5,9H2,1-2H3,(H,10,11)/t7-/m0/s1
|
||||
InChIKey |
AYXYPKUFHZROOJ-ZETCQYMHSA-N
|
||||
CAS Number |
CAS 148553-50-8
|
||||
ChEBI ID | |||||
TTD Drug ID |
Combinatorial Therapeutic Effect(s) Validated Clinically or Experimentally | ||||||
---|---|---|---|---|---|---|
α. A List of Drug(s) Whose Efficacy can be Enhanced by This NP | ||||||
Tapentadol | Acute pain | Click to Show/Hide the Molecular Data of This Drug | ||||
Achieving Therapeutic Synergy | Click to Show/Hide | |||||
Representative Experiment Reporting the Effect of This Combination | [2] | |||||
Detail(s) | Combination Info click to show the detail info of this combination | |||||
In-vivo Model | For a xenograft model: Male Sprague Dawley rats (120-140 g) were anaesthetized with isoflurane, and arthritis was induced in the left knee by an intrarticular injection of 2 mg MIA in 25 ul of 0.9% saline. | |||||
Experimental
Result(s) |
The combination therapy of tapentadol and pregabalin restored descending noradrenergic inhibitory tone and also inhibited nociceptive transmission at the level of the spinal cord can provide superior analgesia. |
Target and Pathway | ||||
---|---|---|---|---|
Target(s) | Calcium channel alpha-2/delta-1 (CACNA2D1) | Molecule Info | [3] | |
KEGG Pathway | MAPK signaling pathway | Click to Show/Hide | ||
2 | Cardiac muscle contraction | |||
3 | Adrenergic signaling in cardiomyocytes | |||
4 | Oxytocin signaling pathway | |||
5 | Hypertrophic cardiomyopathy (HCM) | |||
6 | Arrhythmogenic right ventricular cardiomyopathy (ARVC) | |||
7 | Dilated cardiomyopathy | |||
Panther Pathway | Muscarinic acetylcholine receptor 2 and 4 signaling pathway | Click to Show/Hide | ||
WikiPathways | Arrhythmogenic Right Ventricular Cardiomyopathy | Click to Show/Hide | ||
2 | miR-targeted genes in muscle cell - TarBase | |||
3 | miR-targeted genes in lymphocytes - TarBase |